Cancer Treatment Centers of America Introduce new Chief of Gynecologic Oncology
Cancers of the female reproductive tract continue to remain a common problem today. These cancers can include uterine tumors, cervical cancer, vaginal and vulvar cancers, as well as ovarian tumors. Today’s cancer patients desire to have the best and most scientifically advanced treatment options available to them, and Cancer Treatment Centers of America happens to specialize in these types of treatments.
Cancer Treatment Centers of America recently announced that they have a new chief of gynecologic oncology. Dr. Julian Schink has been brought on board to assist as Medical Director of gynecologic oncology, as well as serving as chief of this program. Dr. Schink will be working at the CTCA located in Zion, Illinois. Julian Schink is a critically acclaimed board certified oncologist who specializes in the treatment of gynecologic cancers. He has many years of experience in using targeted chemotherapy, hormone therapy, advanced surgical techniques, and other targeted therapies to treat cancers of the female reproductive tract.
Dr. Schink’s Role at CTCA
Dr. Schink says he feels honored to be joining a world-renowned cancer treatment center and as a dedicated oncologist, he has a burning desire to provide the best regarding treatment options for all patients who enter his doors. He is committed to providing personalized care of the highest quality for all of his patients. Scientific advances in the field of gynecological cancers have allowed physicians such as Dr. Schink to provide the kind of care that turns cancer victims into long term survivors, and he is proud to play a part in helping women win the fight against these illnesses.
The Gynecologic Oncology Program
Cancer Treatment Centers of America boasts a large and advanced gynecological oncology program. This program includes some of the most technologically advanced cancer therapies that exist in modern medicine today. This program includes the following treatment modalities:
* Robotic Surgery
The da Vinci surgery system can allow surgeons to perform complex operations in a minimally invasive manner that improves the comfort and speeds the healing time for their patients. Because only tiny incisions are made with this type of surgery, patients experience less pain up waking up, and they heal much faster, allowing them to get back to their usual daily routine faster than ever before. Other benefits of the da Vinci surgical method include less blood loss, shorter hospital stays, a lowered risk of infection in surgical wounds, less scarring, and fewer long term complications to surgery.
* Nationally Recognized Tumor Board
Dr. Schink and his team of qualified medical professionals are working to create a national tumor board that will provide colleagues with valuable insight from their peers from all across the nation. Several similar types of boards have already proven very successful at providing health professionals with the kind of information that will help them provide better outcomes for their patients.
* Hyperthermic intraperitoneal chemotherapy (HIPEC)
HIPEC is a scientifically advanced method of delivering powerful chemotherapy drugs directly to the tumor, reducing side effects and improve the effectiveness of the treatment. This treatment modality is for use with patients who have experienced advanced spread of their cancer within the abdominal cavity but who have not had their cancer spread outside of the abdomen. Delivering chemotherapy drugs in such a precise manner only to the area affected by the cancer allows for higher doses of the drugs to be used without creating serious side effects that typically accompany these high-dose treatments. It also allows for a higher amount of the drug to be absorbed by the body, creating a better outcome for treatment with a reduction in bothersome symptoms.
Dr. Schink’s Medical Background
Dr. Schink is coming to Cancer Treatment Centers of America from Spectrum Health, where he previously served as the vice president of integration. He has a long career with many accomplishments including serving as a professor at the University of Wisconsin Medical School. He has also been involved in some clinical trials designed to study the effects and success rates of various cancer therapies. He is licensed in both Illinois and Michigan and is a member of several prominent medical organizations.